Last updated on December 2016

Trial of Switching Between Intravitreal Bevacizumab (Avastin )& Intravitreal Dexamethasone (Ozurdex ) for Persistent Diabetic Macular Oedema


Brief description of study

The specific aim of the study is to test the following hypothesis: That switching between treatments from bevacizumab to Ozurdex or vice versa in eyes with diabetic macular oedema with no or incomplete response from one therapy is beneficial.

Detailed Study Description

A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)

Clinical Study Identifier: NCT01787669

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

SAMANTHA FRASER-BELL

Sydney Eye Hospital
Sydney, Australia
  Connect »

Lyndell Lim

Centre for Eye Research Australia (Royal Victorian Eye & Ear Hospital)
Melbourne, Australia
  Connect »

Samantha FRASER-BELL

Lions Eye Institute
Perth, Australia
  Connect »